-
1
-
-
6344253356
-
Antiinflammatory properties of HDL
-
Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-772.
-
(2004)
Circ Res.
, vol.95
, pp. 764-772
-
-
Barter, P.J.1
Nicholls, S.2
Rye, K.A.3
Anantharamaiah, G.M.4
Navab, M.5
Fogelman, A.M.6
-
2
-
-
21844467979
-
New insights into the regulation of HDL metabolism and reverse cholesterol transport
-
Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.
-
(2005)
Circ Res.
, vol.96
, pp. 1221-1232
-
-
Lewis, G.F.1
Rader, D.J.2
-
3
-
-
79952222810
-
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events
-
Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410.
-
(2011)
Clin Chem.
, vol.57
, pp. 392-410
-
-
Rosenson, R.S.1
Brewer Jr., H.B.2
Chapman, M.J.3
Fazio, S.4
Hussain, M.M.5
Kontush, A.6
Krauss, R.M.7
Otvos, J.D.8
Remaley, A.T.9
Schaefer, E.J.10
-
4
-
-
0024996141
-
Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
-
Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
-
(1990)
J Clin Invest.
, vol.86
, pp. 379-384
-
-
Tall, A.R.1
-
5
-
-
34547700634
-
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo
-
Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216-2224.
-
(2007)
J Clin Invest.
, vol.117
, pp. 2216-2224
-
-
Wang, X.1
Collins, H.L.2
Ranalletta, M.3
Fuki, I.V.4
Billheimer, J.T.5
Rothblat, G.H.6
Tall, A.R.7
Rader, D.J.8
-
6
-
-
11144246298
-
Scavenger receptor class B type i is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice
-
Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, Twisk J, Van Berkel TJ. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res. 2004;45:2088-2095.
-
(2004)
J Lipid Res.
, vol.45
, pp. 2088-2095
-
-
Out, R.1
Hoekstra, M.2
Spijkers, J.A.3
Kruijt, J.K.4
Van Eck, M.5
Bos, I.S.6
Twisk, J.7
Van Berkel, T.J.8
-
7
-
-
33646678433
-
Cholesteryl ester transfer protein inhibition: Effect on reverse cholesterol transport?
-
Rensen PC, Havekes LM. Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:681-684.
-
(2006)
Arterioscler Thromb Vasc Biol.
, vol.26
, pp. 681-684
-
-
Rensen, P.C.1
Havekes, L.M.2
-
8
-
-
0030058583
-
Hepatic lipase gene therapy in hepatic lipase-deficient mice: Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium
-
Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB Jr, Santamarina-Fojo S. Hepatic lipase gene therapy in hepatic lipase-deficient mice: adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest. 1996;97:799-805.
-
(1996)
J Clin Invest.
, vol.97
, pp. 799-805
-
-
Applebaum-Bowden, D.1
Kobayashi, J.2
Kashyap, V.S.3
Brown, D.R.4
Berard, A.5
Meyn, S.6
Parrott, C.7
Maeda, N.8
Shamburek, R.9
Brewer Jr., H.B.10
Santamarina-Fojo, S.11
-
9
-
-
37049244034
-
The role of lipids and lipoproteins in atherosclerosis
-
Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-171.
-
(1950)
Science.
, vol.111
, pp. 166-171
-
-
Gofman, J.W.1
Lindgren, F.2
-
10
-
-
0016433018
-
Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
-
Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
-
(1975)
Lancet.
, vol.1
, pp. 16-19
-
-
Miller, G.J.1
Miller, N.E.2
-
11
-
-
0017280786
-
Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men
-
Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med. 1976;294:293-298.
-
(1976)
N Engl J Med.
, vol.294
, pp. 293-298
-
-
Rhoads, G.G.1
Gulbrandsen, C.L.2
Kagan, A.3
-
12
-
-
0017384270
-
High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study
-
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
-
(1977)
Am J Med.
, vol.62
, pp. 707-714
-
-
Gordon, T.1
Castelli, W.P.2
Hjortland, M.C.3
Kannel, W.B.4
Dawber, T.R.5
-
13
-
-
0017614773
-
The Tromsø heart-study: High-density lipoprotein and coronary heart-disease: A prospective casecontrol study
-
Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study: high-density lipoprotein and coronary heart-disease: a prospective casecontrol study. Lancet. 1977;1:965-968.
-
(1977)
Lancet.
, vol.1
, pp. 965-968
-
-
Miller, N.E.1
Thelle, D.S.2
Forde, O.H.3
Mjos, O.D.4
-
14
-
-
0034496618
-
HDLcholesterol as a marker of coronary heart disease risk: The Québec cardiovascular study
-
Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDLcholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis. 2000;153:263-272.
-
(2000)
Atherosclerosis.
, vol.153
, pp. 263-272
-
-
Després, J.P.1
Lemieux, I.2
Dagenais, G.R.3
Cantin, B.4
Lamarche, B.5
-
15
-
-
70450081001
-
Major lipids, apolipoproteins, and risk of vascular disease
-
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009;302:1993-2000.
-
(2009)
Jama.
, vol.302
, pp. 1993-2000
-
-
Di Angelantonio, E.1
Sarwar, N.2
Perry, P.3
Kaptoge, S.4
Ray, K.K.5
Thompson, A.6
Wood, A.M.7
Lewington, S.8
Sattar, N.9
Packard, C.J.10
Collins, R.11
Thompson, S.G.12
Danesh, J.13
-
16
-
-
0017040704
-
Longevity syndromes: Familial hypobeta and familial hyperalpha lipoproteinemia
-
Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88:941-957.
-
(1976)
J Lab Clin Med.
, vol.88
, pp. 941-957
-
-
Glueck, C.J.1
Gartside, P.2
Fallat, R.W.3
Sielski, J.4
Steiner, P.M.5
-
17
-
-
0023232216
-
Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
-
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
-
(1987)
N Engl J Med.
, vol.317
, pp. 1237-1245
-
-
Frick, M.H.1
Elo, O.2
Haapa, K.3
Heinonen, O.P.4
Heinsalmi, P.5
Helo, P.6
Huttunen, J.K.7
Kaitaniemi, P.8
Koskinen, P.9
Manninen, V.10
-
18
-
-
0026754428
-
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Münster study
-
Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Münster study. Am J Cardiol. 1992;70:733-737.
-
(1992)
Am J Cardiol.
, vol.70
, pp. 733-737
-
-
Assmann, G.1
Schulte, H.2
-
19
-
-
34447511196
-
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
-
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
-
(2007)
JAMA.
, vol.298
, pp. 299-308
-
-
Nordestgaard, B.G.1
Benn, M.2
Schnohr, P.3
Tybjaerg-Hansen, A.4
-
20
-
-
0034739457
-
Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study
-
Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation. 2000;102:2197-2203.
-
(2000)
Circulation.
, vol.102
, pp. 2197-2203
-
-
Agerholm-Larsen, B.1
Tybjaerg-Hansen, A.2
Schnohr, P.3
Steffensen, R.4
Nordestgaard, B.G.5
-
21
-
-
0034712706
-
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
-
Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000;101:1907-1912.
-
(2000)
Circulation.
, vol.101
, pp. 1907-1912
-
-
Agerholm-Larsen, B.1
Nordestgaard, B.G.2
Steffensen, R.3
Jensen, G.4
Tybjaerg-Hansen, A.5
-
22
-
-
0036228585
-
A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes
-
Hokanson JE, Cheng S, Snell-Bergeon JK, Fijal BA, Grow MA, Hung C, Erlich HA, Ehrlich J, Eckel RH, Rewers M. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes. 2002;51:1208-1213.
-
(2002)
Diabetes.
, vol.51
, pp. 1208-1213
-
-
Hokanson, J.E.1
Cheng, S.2
Snell-Bergeon, J.K.3
Fijal, B.A.4
Grow, M.A.5
Hung, C.6
Erlich, H.A.7
Ehrlich, J.8
Eckel, R.H.9
Rewers, M.10
-
23
-
-
0038798088
-
Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: The Copenhagen City Heart Study
-
Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol. 2003;41:1972-1982.
-
(2003)
J Am Coll Cardiol.
, vol.41
, pp. 1972-1982
-
-
Andersen, R.V.1
Wittrup, H.H.2
Tybjaerg-Hansen, A.3
Steffensen, R.4
Schnohr, P.5
Nordestgaard, B.G.6
-
24
-
-
84864845456
-
Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study
-
Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
-
(2012)
Lancet.
, vol.380
, pp. 572-580
-
-
Voight, B.F.1
Peloso, G.M.2
Orho-Melander, M.3
Frikke-Schmidt, R.4
Barbalic, M.5
Jensen, M.K.6
Hindy, G.7
Hólm, H.8
Ding, E.L.9
Johnson, T.10
Schunkert, H.11
Samani, N.J.12
Clarke, R.13
Hopewell, J.C.14
Thompson, J.F.15
Li, M.16
Thorleifsson, G.17
Newton-Cheh, C.18
Musunuru, K.19
Pirruccello, J.P.20
Saleheen, D.21
Chen, L.22
Stewart, A.23
Schillert, A.24
Thorsteinsdottir, U.25
Thorgeirsson, G.26
Anand, S.27
Engert, J.C.28
Morgan, T.29
Spertus, J.30
Stoll, M.31
Berger, K.32
Martinelli, N.33
Girelli, D.34
McKeown, P.P.35
Patterson, C.C.36
Epstein, S.E.37
Devaney, J.38
Burnett, M.S.39
Mooser, V.40
Ripatti, S.41
Surakka, I.42
Nieminen, M.S.43
Sinisalo, J.44
Lokki, M.L.45
Perola, M.46
Havulinna, A.47
De Faire, U.48
Gigante, B.49
Ingelsson, E.50
Zeller, T.51
Wild, P.52
De Bakker, P.I.53
Klungel, O.H.54
Maitland-Van Der Zee, A.H.55
Peters, B.J.56
De Boer, A.57
Grobbee, D.E.58
Kamphuisen, P.W.59
Deneer, V.H.60
Elbers, C.C.61
Onland-Moret, N.C.62
Hofker, M.H.63
Wijmenga, C.64
Verschuren, W.M.65
Boer, J.M.66
Van Der Schouw, Y.T.67
Rasheed, A.68
Frossard, P.69
Demissie, S.70
Willer, C.71
Do, R.72
Ordovas, J.M.73
Abecasis, G.R.74
Boehnke, M.75
Mohlke, K.L.76
Daly, M.J.77
Guiducci, C.78
Burtt, N.P.79
Surti, A.80
Gonzalez, E.81
Purcell, S.82
Gabriel, S.83
Marrugat, J.84
Peden, J.85
Erdmann, J.86
Diemert, P.87
Willenborg, C.88
König, I.R.89
Fischer, M.90
Hengstenberg, C.91
Ziegler, A.92
Buysschaert, I.93
Lambrechts, D.94
Van De Werf, F.95
Fox, K.A.96
El Mokhtari, N.E.97
Rubin, D.98
Schrezenmeir, J.99
more..
-
25
-
-
84892679085
-
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
-
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA.
-
JAMA
-
-
-
26
-
-
0032917975
-
Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression
-
Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105-1110.
-
(1999)
Arterioscler Thromb Vasc Biol.
, vol.19
, pp. 1105-1110
-
-
Plump, A.S.1
Masucci-Magoulas, L.2
Bruce, C.3
Bisgaier, C.L.4
Breslow, J.L.5
Tall, A.R.6
-
27
-
-
33750213836
-
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice
-
Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26:2552-2559.
-
(2006)
Arterioscler Thromb Vasc Biol.
, vol.26
, pp. 2552-2559
-
-
Westerterp, M.1
Van Der Hoogt, C.C.2
De Haan, W.3
Offerman, E.H.4
Dallinga-Thie, G.M.5
Jukema, J.W.6
Havekes, L.M.7
Rensen, P.C.8
-
28
-
-
68949207221
-
Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice
-
de Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, Rensen PC. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis. 2009;206:153-158.
-
(2009)
Atherosclerosis.
, vol.206
, pp. 153-158
-
-
De Vries-Van Der Weij, J.1
Zadelaar, S.2
Toet, K.3
Havekes, L.M.4
Kooistra, T.5
Rensen, P.C.6
-
29
-
-
0033822810
-
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
-
Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106-2112.
-
(2000)
Arterioscler Thromb Vasc Biol.
, vol.20
, pp. 2106-2112
-
-
Rittershaus, C.W.1
Miller, D.P.2
Thomas, L.J.3
Picard, M.D.4
Honan, C.M.5
Emmett, C.D.6
Pettey, C.L.7
Adari, H.8
Hammond, R.A.9
Beattie, D.T.10
Callow, A.D.11
Marsh, H.C.12
Ryan, U.S.13
-
30
-
-
0032570684
-
Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
-
Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
-
(1998)
J Biol Chem.
, vol.273
, pp. 5033-5036
-
-
Sugano, M.1
Makino, N.2
Sawada, S.3
Otsuka, S.4
Watanabe, M.5
Okamoto, H.6
Kamada, M.7
Mizushima, A.8
-
31
-
-
74549148035
-
Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
-
Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.
-
(2010)
Eur Heart J.
, vol.31
, pp. 149-164
-
-
Chapman, M.J.1
Le Goff, W.2
Guerin, M.3
Kontush, A.4
-
32
-
-
39449098454
-
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
-
de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, Havekes LM, Rensen PC. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis. 2008;197:57-63.
-
(2008)
Atherosclerosis.
, vol.197
, pp. 57-63
-
-
De Haan, W.1
Van Der Hoogt, C.C.2
Westerterp, M.3
Hoekstra, M.4
Dallinga-Thie, G.M.5
Princen, H.M.6
Romijn, J.A.7
Jukema, J.W.8
Havekes, L.M.9
Rensen, P.C.10
-
33
-
-
34548157559
-
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
-
van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007;48:1763-1771.
-
(2007)
J Lipid Res.
, vol.48
, pp. 1763-1771
-
-
Van Der Hoogt, C.C.1
De Haan, W.2
Westerterp, M.3
Hoekstra, M.4
Dallinga-Thie, G.M.5
Romijn, J.A.6
Princen, H.M.7
Jukema, J.W.8
Havekes, L.M.9
Rensen, P.C.10
-
34
-
-
55449114841
-
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice
-
van der Hoorn JW, de Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HM. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol. 2008;28:2016-2022.
-
(2008)
Arterioscler Thromb Vasc Biol.
, vol.28
, pp. 2016-2022
-
-
Van Der Hoorn, J.W.1
De Haan, W.2
Berbée, J.F.3
Havekes, L.M.4
Jukema, J.W.5
Rensen, P.C.6
Princen, H.M.7
-
35
-
-
0025104275
-
Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
-
Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
-
(1990)
N Engl J Med.
, vol.323
, pp. 1234-1238
-
-
Inazu, A.1
Brown, M.L.2
Hesler, C.B.3
Agellon, L.B.4
Koizumi, J.5
Takata, K.6
Maruhama, Y.7
Mabuchi, H.8
Tall, A.R.9
-
36
-
-
16944362351
-
Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity
-
Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-1059.
-
(1997)
Arterioscler Thromb Vasc Biol.
, vol.17
, pp. 1053-1059
-
-
Hirano, K.1
Yamashita, S.2
Nakajima, N.3
Arai, T.4
Maruyama, T.5
Yoshida, Y.6
Ishigami, M.7
Sakai, N.8
Kameda-Takemura, K.9
Matsuzawa, Y.10
-
37
-
-
45349105911
-
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
-
Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-2788.
-
(2008)
JAMA.
, vol.299
, pp. 2777-2788
-
-
Thompson, A.1
Di Angelantonio, E.2
Sarwar, N.3
Erqou, S.4
Saleheen, D.5
Dullaart, R.P.6
Keavney, B.7
Ye, Z.8
Danesh, J.9
-
38
-
-
67649367650
-
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study
-
Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2:26-33.
-
(2009)
Circ Cardiovasc Genet.
, vol.2
, pp. 26-33
-
-
Ridker, P.M.1
Paré, G.2
Parker, A.N.3
Zee, R.Y.4
Miletich, J.P.5
Chasman, D.I.6
-
39
-
-
84868530968
-
Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects
-
Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60:2041-2048.
-
(2012)
J Am Coll Cardiol.
, vol.60
, pp. 2041-2048
-
-
Johannsen, T.H.1
Frikke-Schmidt, R.2
Schou, J.3
Nordestgaard, B.G.4
Tybjærg-Hansen, A.5
-
40
-
-
56449118071
-
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: An adverse pharmacogenetic interaction
-
Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, Bots ML, Doevendans PA. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792-2799.
-
(2008)
Eur Heart J.
, vol.29
, pp. 2792-2799
-
-
Regieli, J.J.1
Jukema, J.W.2
Grobbee, D.E.3
Kastelein, J.J.4
Kuivenhoven, J.A.5
Zwinderman, A.H.6
Van Der Graaf, Y.7
Bots, M.L.8
Doevendans, P.A.9
-
41
-
-
73349122606
-
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community
-
Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120:2414-2420.
-
(2009)
Circulation.
, vol.120
, pp. 2414-2420
-
-
Vasan, R.S.1
Pencina, M.J.2
Robins, S.J.3
Zachariah, J.P.4
Kaur, G.5
D'Agostino, R.B.6
Ordovas, J.M.7
-
42
-
-
33644775588
-
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
-
Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-552.
-
(2006)
J Lipid Res.
, vol.47
, pp. 537-552
-
-
Clark, R.W.1
Ruggeri, R.B.2
Cunningham, D.3
Bamberger, M.J.4
-
43
-
-
34447265547
-
RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial
-
Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153-160.
-
(2007)
Lancet.
, vol.370
, pp. 153-160
-
-
Bots, M.L.1
Visseren, F.L.2
Evans, G.W.3
Riley, W.A.4
Revkin, J.H.5
Tegeler, C.H.6
Shear, C.L.7
Duggan, W.T.8
Vicari, R.M.9
Grobbee, D.E.10
Kastelein, J.J.11
-
44
-
-
34247241088
-
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
-
RADIANCE 1 Investigators
-
Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
-
(2007)
N Engl J Med.
, vol.356
, pp. 1620-1630
-
-
Kastelein, J.J.1
Van Leuven, S.I.2
Burgess, L.3
Evans, G.W.4
Kuivenhoven, J.A.5
Barter, P.J.6
Revkin, J.H.7
Grobbee, D.E.8
Riley, W.A.9
Shear, C.L.10
Duggan, W.T.11
Bots, M.L.12
-
45
-
-
34047106220
-
Effect of torcetrapib on the progression of coronary atherosclerosis
-
ILLUSTRATE Investigators
-
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
-
(2007)
N Engl J Med.
, vol.356
, pp. 1304-1316
-
-
Nissen, S.E.1
Tardif, J.C.2
Nicholls, S.J.3
Revkin, J.H.4
Shear, C.L.5
Duggan, W.T.6
Ruzyllo, W.7
Bachinsky, W.B.8
Lasala, G.P.9
Lasala, G.P.10
Tuzcu, E.M.11
-
46
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
ILLUMINATE Investigators
-
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
-
(2007)
N Engl J Med.
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
Grundy, S.M.4
Kastelein, J.J.5
Komajda, M.6
Lopez-Sendon, J.7
Mosca, L.8
Tardif, J.C.9
Waters, D.D.10
Shear, C.L.11
Revkin, J.H.12
Buhr, K.A.13
Fisher, M.R.14
Tall, A.R.15
Brewer, B.16
-
47
-
-
43449114204
-
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
-
de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 2008;117:2515-2522.
-
(2008)
Circulation.
, vol.117
, pp. 2515-2522
-
-
De Haan, W.1
De Vries-Van Der Weij, J.2
Van Der Hoorn, J.W.3
Gautier, T.4
Van Der Hoogt, C.C.5
Westerterp, M.6
Romijn, J.A.7
Jukema, J.W.8
Havekes, L.M.9
Princen, H.M.10
Rensen, P.C.11
-
48
-
-
48149106322
-
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
-
Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M III, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-1473.
-
(2008)
Br J Pharmacol.
, vol.154
, pp. 1465-1473
-
-
Forrest, M.J.1
Bloomfield, D.2
Briscoe, R.J.3
Brown, P.N.4
Cumiskey, A.M.5
Ehrhart, J.6
Hershey, J.C.7
Keller, W.J.8
Ma, X.9
McPherson, H.E.10
Messina, E.11
Peterson, L.B.12
Sharif-Rodriguez, W.13
Siegl, P.K.14
Sinclair, P.J.15
Sparrow, C.P.16
Stevenson, A.S.17
Sun, S.Y.18
Tsai, C.19
Vargas, H.20
Walker III, M.21
West, S.H.22
White, V.23
Woltmann, R.F.24
more..
-
49
-
-
77952992021
-
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition
-
Connelly MA, Parry TJ, Giardino EC, Huang Z, Cheung WM, Chen C, Cools F, Van der Linde H, Gallacher DJ, Kuo GH, Sarich TC, Demarest KT, Damiano BP. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol. 2010;55:459-468.
-
(2010)
J Cardiovasc Pharmacol.
, vol.55
, pp. 459-468
-
-
Connelly, M.A.1
Parry, T.J.2
Giardino, E.C.3
Huang, Z.4
Cheung, W.M.5
Chen, C.6
Cools, F.7
Van Der Linde, H.8
Gallacher, D.J.9
Kuo, G.H.10
Sarich, T.C.11
Demarest, K.T.12
Damiano, B.P.13
-
50
-
-
71749117559
-
Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
-
Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(suppl 10):10E-15E.
-
(2009)
Am J Cardiol.
, vol.104
, Issue.SUPPL. 10
-
-
Barter, P.1
-
51
-
-
34247352806
-
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL
-
Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132-1138.
-
(2007)
Arterioscler Thromb Vasc Biol.
, vol.27
, pp. 1132-1138
-
-
Yvan-Charvet, L.1
Matsuura, F.2
Wang, N.3
Bamberger, M.J.4
Nguyen, T.5
Rinninger, F.6
Jiang, X.C.7
Shear, C.L.8
Tall, A.R.9
-
52
-
-
58149386896
-
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
-
Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506-2514.
-
(2008)
Circulation.
, vol.118
, pp. 2506-2514
-
-
Nicholls, S.J.1
Tuzcu, E.M.2
Brennan, D.M.3
Tardif, J.C.4
Nissen, S.E.5
-
53
-
-
0034644214
-
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
-
Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
-
(2000)
Nature.
, vol.406
, pp. 203-207
-
-
Okamoto, H.1
Yonemori, F.2
Wakitani, K.3
Minowa, T.4
Maeda, K.5
Shinkai, H.6
-
54
-
-
78650054881
-
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
-
Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443-3454.
-
(2010)
J Lipid Res.
, vol.51
, pp. 3443-3454
-
-
Niesor, E.J.1
Magg, C.2
Ogawa, N.3
Okamoto, H.4
Von Der Mark, E.5
Matile, H.6
Schmid, G.7
Clerc, R.G.8
Chaput, E.9
Blum-Kaelin, D.10
Huber, W.11
Thoma, R.12
Pflieger, P.13
Kakutani, M.14
Takahashi, D.15
Dernick, G.16
Maugeais, C.17
-
55
-
-
17444372760
-
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
-
Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD, Kastelein JJ. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085-1088.
-
(2005)
Am J Cardiol.
, vol.95
, pp. 1085-1088
-
-
Kuivenhoven, J.A.1
De Grooth, G.J.2
Kawamura, H.3
Klerkx, A.H.4
Wilhelm, F.5
Trip, M.D.6
Kastelein, J.J.7
-
56
-
-
84863789387
-
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
-
Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53:1755-1766.
-
(2012)
J Lipid Res.
, vol.53
, pp. 1755-1766
-
-
Barter, P.J.1
Rye, K.A.2
-
57
-
-
77954958496
-
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
-
Clerc RG, Stauffer A, Weibel F, Hainaut E, Perez A, Hoflack JC, Bénardeau A, Pflieger P, Garriz JM, Funder JW, Capponi AM, Niesor EJ. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertens. 2010;28:1676-1686.
-
(2010)
J Hypertens.
, vol.28
, pp. 1676-1686
-
-
Clerc, R.G.1
Stauffer, A.2
Weibel, F.3
Hainaut, E.4
Perez, A.5
Hoflack, J.C.6
Bénardeau, A.7
Pflieger, P.8
Garriz, J.M.9
Funder, J.W.10
Capponi, A.M.11
Niesor, E.J.12
-
58
-
-
71249121107
-
Dalcetrapib: No off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats
-
Stroes ES, Kastelein JJ, Bénardeau A, Kuhlmann O, Blum D, Campos LA, Clerc RG, Niesor EJ. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol. 2009;158:1763-1770.
-
(2009)
Br J Pharmacol.
, vol.158
, pp. 1763-1770
-
-
Stroes, E.S.1
Kastelein, J.J.2
Bénardeau, A.3
Kuhlmann, O.4
Blum, D.5
Campos, L.A.6
Clerc, R.G.7
Niesor, E.J.8
-
59
-
-
80255122648
-
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial
-
dal-PLAQUE Investigators
-
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547-1559.
-
(2011)
Lancet.
, vol.378
, pp. 1547-1559
-
-
Fayad, Z.A.1
Mani, V.2
Woodward, M.3
Kallend, D.4
Abt, M.5
Burgess, T.6
Fuster, V.7
Ballantyne, C.M.8
Stein, E.A.9
Tardif, J.C.10
Rudd, J.H.11
Farkouh, M.E.12
Tawakol, A.13
-
60
-
-
84859517252
-
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial
-
dal-VESSEL Investigators
-
Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-865.
-
(2012)
Eur Heart J.
, vol.33
, pp. 857-865
-
-
Lüscher, T.F.1
Taddei, S.2
Kaski, J.C.3
Jukema, J.W.4
Kallend, D.5
Münzel, T.6
Kastelein, J.J.7
Deanfield, J.E.8
-
61
-
-
70749131522
-
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
-
dal-OUTCOMES Committees and Investigators
-
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896-901.e3.
-
(2009)
Am Heart J.
, vol.158
-
-
Schwartz, G.G.1
Olsson, A.G.2
Ballantyne, C.M.3
Barter, P.J.4
Holme, I.M.5
Kallend, D.6
Leiter, L.A.7
Leitersdorf, E.8
McMurray, J.J.9
Shah, P.K.10
Tardif, J.C.11
Chaitman, B.R.12
Duttlinger-Maddux, R.13
Mathieson, J.14
-
62
-
-
84870045994
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome
-
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl JMed. 2012.
-
(2012)
N Engl JMed.
-
-
Schwartz, G.G.1
Olsson, A.G.2
Abt, M.3
Ballantyne, C.M.4
Barter, P.J.5
Brumm, J.6
Chaitman, B.R.7
Holme, I.M.8
Kallend, D.9
Leiter, L.A.10
Leitersdorf, E.11
Jjv, M.12
Mundl, H.13
Nicholls, S.J.14
Shah, P.K.15
Tardif, J.-C.16
Wright, R.S.17
-
63
-
-
77956513064
-
Biochemical characterization of cholesteryl ester transfer protein inhibitors
-
Ranalletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E, Houde C, Elowe NH, Garcia-Calvo M, Porter G, Eveland S, Frantz-Wattley B, Kavana M, Addona G, Sinclair P, Sparrow C, O'Neill EA, Koblan KS, Sitlani A, Hubbard B, Fisher TS. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51:2739-2752.
-
(2010)
J Lipid Res.
, vol.51
, pp. 2739-2752
-
-
Ranalletta, M.1
Bierilo, K.K.2
Chen, Y.3
Milot, D.4
Chen, Q.5
Tung, E.6
Houde, C.7
Elowe, N.H.8
Garcia-Calvo, M.9
Porter, G.10
Eveland, S.11
Frantz-Wattley, B.12
Kavana, M.13
Addona, G.14
Sinclair, P.15
Sparrow, C.16
O'Neill, E.A.17
Koblan, K.S.18
Sitlani, A.19
Hubbard, B.20
Fisher, T.S.21
more..
-
64
-
-
78549235583
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease
-
Determining the Efficacy and Tolerability Investigators
-
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2406-2415
-
-
Cannon, C.P.1
Shah, S.2
Dansky, H.M.3
Davidson, M.4
Brinton, E.A.5
Gotto, A.M.6
Stepanavage, M.7
Liu, S.X.8
Gibbons, P.9
Ashraf, T.B.10
Zafarino, J.11
Mitchel, Y.12
Barter, P.13
-
65
-
-
81255125373
-
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial
-
Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-2109.
-
(2011)
JAMA.
, vol.306
, pp. 2099-2109
-
-
Nicholls, S.J.1
Brewer, H.B.2
Kastelein, J.J.3
Krueger, K.A.4
Wang, M.D.5
Shao, M.6
Hu, B.7
McErlean, E.8
Nissen, S.E.9
-
66
-
-
78651379500
-
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
-
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
-
(2011)
N Engl J Med.
, vol.364
, pp. 127-135
-
-
Khera, A.V.1
Cuchel, M.2
De La Llera-Moya, M.3
Rodrigues, A.4
Burke, M.F.5
Jafri, K.6
French, B.C.7
Phillips, J.A.8
Mucksavage, M.L.9
Wilensky, R.L.10
Mohler, E.R.11
Rothblat, G.H.12
Rader, D.J.13
-
67
-
-
79960205374
-
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
European Society of Cardiology (ESC); European Atherosclerosis Society (EAS)
-
Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3-46.
-
(2011)
Atherosclerosis.
, vol.217
, pp. 3-46
-
-
Catapano, A.L.1
Reiner, Z.2
De Backer, G.3
Graham, I.4
Taskinen, M.R.5
Wiklund, O.6
Agewall, S.7
Alegria, E.8
Chapman, M.9
Durrington, P.10
Erdine, S.11
Halcox, J.12
Hobbs, R.13
Kjekshus, J.14
Filardi, P.P.15
Riccardi, G.16
Storey, R.F.17
Wood, D.18
|